NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Crinetics Pharmaceuticals, Inc. CRNX
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$7.7M
▲ 640.7% vs FY2024
EPS · FY25
$-4.95
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-40.2%
Net margin · FY25
-6046.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 7.7M
Revenue, FY2025 · full 10-year series below
Revenue
Net income
The company lost 6046 cents on every revenue dollar this year.
Per share
USD -4.95
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-40.2%
Return on equity, FY2025
ROE
Operating margin-6714.8%
Net margin-6046.2%
Return on assets-36.3%
Each USD of equity lost 40 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+155.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+17.6%
+155.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2025
Change, 5 years+189.6%
Change, 10 years—
The share count grew 190% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.1B
total assets, end of FY2025
Total assetsUSD 1.1B
EquityUSD 992.1M
CashUSD 101.5M
Current ratio12.32×
Equity funds 88% of total assets.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.5
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.5
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.5
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−4.95
−3.69
−3.69
−3.15
−2.80
−2.42
−2.09
−2.23
−6.68
−5.96
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
−40.2
−32.0
−50.2
−50.6
−43.0
−51.6
−36.4
−37.3
·
·
Shares out B
0.10
0.09
0.07
0.05
0.05
0.03
0.02
0.00
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
28 of 28
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed